Why activated protein C was not successful in severe sepsis and septic shock: Are we still tilting at windmills?

Current Infectious Disease Reports

Volumn 15, Issue 5, 2013, Pages 407-412

  Lai, Peggy S ^a   Thompson, B Taylor ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drotrecogin alfa activated; Protein C; Sepsis; Septic shock; Systemic inflammatory response syndrome

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; DROTRECOGIN; NORADRENALIN; PLACEBO;

ANTIBIOTIC THERAPY; ARTERY CATHETERIZATION; BLOOD CLOTTING DISORDER; CATHETER; DRUG EFFICACY; DRUG QUALITY; HEALTH CARE COST; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; PHENOTYPE; PULMONARY ARTERY CATHETER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84884596867     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0358-9     Document Type: Review

References (41)

1. Jawad I, Luksic I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health. 2012;2(1):10404. PubMed PMID: 23198133. Pubmed Central PMCID: 3484761.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10. PubMed PMID: 11445675.
3. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-53. PubMed PMID: 16424713. Epub 2006/01/21. eng.
4. Russell JA. Management of sepsis. N Engl J Med. 2006;355(16):1699-713. PubMed PMID: 17050894. Epub 2006/10/20. eng.
5. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA. 2008;299(19):2294-303. PubMed PMID: 18492971. Epub 2008/05/22. eng.
6. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38(2):367-74. PubMed PMID: 20035219.
7. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709. English.
8. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit care. 2007;11 Suppl 5:S3. PubMed PMID: 18269690. Pubmed Central PMCID: 2230607.
9. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. 2002;30(5 Suppl):S288-93. PubMed PMID: 12004250. Epub 2002/05/11. eng.
10. Schouten M. van 't Veer C, Roelofs JJ, Gerlitz B, Grinnell BW, Levi M, et al. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Thromb Haemost. 2011;106(6):1189-96.
11. Food Drug Administration Center for Drugs Evaluation Research. FDA briefing document: drotrecogin alfa (activated)[recombinant human activated protein C (rhAPC)] Xigris, BLA# 125029/0. Anti-Infective Advisory Committee. Rockville, Md: FDA Maryland; 2001.
12. Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New Engl J Med. 2005;353(13):1332-41. English.
13. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007;369(9564):836-43. English.
14. Dhainaut JF, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, et al. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med. 2009;35(7):1187-95. English.
15. •• Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. New Engl J Med. 2012;366(21):1-10. Randomized controlled clinical trial of DAA vs. placebo in adults with refractory septic shock after early goal directed therapy which did not demonstrate efficacy of DAA over placebo, leading to the withdrawal of DAA from the market.
16. Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial http://newsroomlillycom/releasedetailcfm?ReleaseID=617602. Accessed May 9, 2012.
17. Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med. 2013;187(10):1091-7. PMID: 23525934.
18. Kubler A, Mayzner-Zawadzka E, Durek G, Gaszynski W, Karpel E, Mikaszewska-Sokolewicz M, et al. Results of severe sepsis treatment program using recombinant human activated protein C in Poland. Med Sci Monit Int Med J Exp Clin Res. 2006;12(3):CR107-12. PubMed PMID: 16501420. Epub 2006/02/28. eng.
19. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med. 2007;33(3):426-34. PubMed PMID: 17325836.
20. Rowan KM, Welch CA, North E, Harrison DA. Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care. 2008;12(2):R58. PubMed PMID: 18430215. Pubmed Central PMCID: PMC2447613. Epub 2008/04/24. eng.
21. Vincent JL, Laterre PF, Decruyenaere J, Spapen H, Raemaekers J, Damas F, et al. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units-an observational study. Acta Clin Belg. 2008;63(1):25-30. PubMed PMID: 18386762. Epub 2008/04/05. eng.
22. Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, et al. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care. 2009;13(3):R103. PubMed PMID: 19566927. Pubmed Central PMCID: 2717475.
23. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009;180(9):861-6. PubMed PMID: 19696442. Epub 2009/08/22. eng.
24. Lindenauer PK, Rothberg MB, Nathanson BH, Pekow PS, Steingrub JS. Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38(4):1101-7. PubMed PMID: 20154607. Epub 2010/02/16. eng.
25. Sadaka F, O'Brien J, Migneron M, Stortz J, Vanston A, Taylor RW. Activated protein C in septic shock: a propensity-matched analysis. Crit Care. 2011;15(2):R89. PubMed PMID: 21385410. Pubmed Central PMCID: PMC3219349. Epub 2011/03/10. eng.
26. Rimmer E, Kumar A, Doucette S, Marshall J, Dial S, Gurka D, et al. Activated protein C and septic shock: a propensity-matched cohort study*. Crit Care Med. 2012;40(11):2974-81. PubMed PMID: 22932397. Epub 2012/08/31. eng.
27. • Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis. 2012;12(9):678-86. PubMed PMID: 22809883. A meta-analysis focused on observational studies suggesting that in clinical practice DAA provides a mortality benefit to patients with septic shock. However this study should be interpreted with caution as observational studies, even after adjustment for measured confounders, may not fully adjust for indication bias.
28. Lai PS, Matteau A, Iddriss A, Hawes JC, Ranieri V, Thompson BT. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock. Minerva Anestesiol. 2013;79(1):33-43. PubMed PMID: 23174922.
29. Connors Jr AF, Speroff T, Dawson NV, Thomas C, Harrell Jr FE, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA. 1996;276(11):889-97. PubMed PMID: 8782638.
30. National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. New Engl J Med. 2006;354(21):2213-24. PubMed PMID: 16714768.
31. Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud D, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2003;290(20):2713-20. PubMed PMID: 14645314.
32. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005;366(9484):472-7. PubMed PMID: 16084255.
33. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625-33. PubMed PMID: 16204662.
34. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med. 2003;348(1):5-14. PubMed PMID: 12510037.
35. Estenssoro E, Rios FG, Apezteguia C, Reina R, Neira J, Ceraso DH, et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med. 2010;182(1):41-8. PubMed PMID: 20203241.
36. Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9(11):1-126. iii-iv. PubMed PMID: 15774234.
37. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med. 2001;345(19):1368-77. English.
38. Gentry CA, Gross KB, Sud B, Drevets DA. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med. 2009;37(1):19-25. PubMed PMID: 19050637.
39. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care. 2006;10(3):R92. English.
40. De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, Scolletta S, et al. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med. 2013;41(3):791-9. PubMed PMID: 23318492.
41. Bone RC. Sepsis clinical trials. Don Quixote revisited. Chest. 1995;107(2):298-9. PubMed PMID: 7842747.